Skip to main content
Fig. 3 | Biology Direct

Fig. 3

From: MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

Fig. 3

MDA19 inhibited migration and invasion and inactivated AKT signaling pathway in HCC cells. HCC cells were treated with MDA19 (30 μM for Hep3B and 40 μM for HepG2) for 48 h. (a) Cell migration and (b) cell invasion were detected by transwell assays. (C) AKT signaling pathway components, including AKT, p-AKT, CDK4, CDK6 and Cyclin D1, were detected by western blot and analyzed by Image J software. All experiments were performed at 3 times. *P < 0.05

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us